Tag Archives: Industry

The Collingwood Group Announces Mortgage Industry Conference Call On the Topic of FHA Claim Filing

Posted on by


Washington, D.C. (PRWEB) July 12, 2012

The Collingwood Group (Collingwood) is pleased to announce its third in a series of industry conference calls — Maximizing FHA Claim Filing (Part A and B), being held at 2pm EST on Thursday, July 26, 2012.

The conversation will focus on the FHA claims process and pitfalls. Specifically, the panelists will provide insight into FHAs highest priorities during a claims review and discuss some of the most common violations they find. Furthermore, Collingwoods team of FHA experts will discuss how much errors cost as well as the most common way servicers leave money on the table that they could be claiming.

The FHA claims filing process is inherently complicated, and if the servicer is not well versed in all the complexities, it can create dual exposurepotential enforcement action by HUD for non-compliance and significant financial losses due to incomplete, inaccurate, or untimely filing, said Brian Montgomery, Collingwood Group Chairman and former FHA Commissioner. He added, How servicers and lenders can effectively manage this process will be the primary focus of this industry call, with a goal of providing information that is timely and insightful.

The call, offered at no cost to participants, will be led by Brian Montgomery. He will be joined by Karen Garner, Collingwood Group Managing Director and Heidi Schranz, Collingwood Group Senior Consultant, who possesses over 10 years of experience in FHA claim processing, filing and auditing.

FHA conducts compliance reviews of servicers filing claims on a routine basis from the largest servicers to those that file only a few claims a year. It is imperative that servicers realize the relationship between how their customer service and loss mitigation representatives service a loan and the filing of the mortgage insurance claim, said Garner With increased emphasis on servicing compliance by FHA, the CFPB, OCC and other regulators, now is the time to ensure that you know what to expect and have policies and procedures in place to minimize the risk to your firm and maximize your mortgage insurance claim recovery.

Collingwoods Risk Management and Compliance Division is sharing information on an ongoing basis with Collingwood clients and other industry colleagues. Its first call FHA Enforcement: Myths, Misconceptions and Facts, focused on FHA Enforcement, Quality Assurance and Inspector General reviews, and the Mortgagee Review Board. The second call focused on FHA Servicing Compliance with emphasis on FHAs loss mitigation program. A summary of each call is available on Collingwoods website at http://www.collingwoodllc.com.

About The Collingwood Group

The Collingwood Group (http://www.collingwoodllc.com) is a Washington, DC-based business advisory firm focused on growing clients businesses, promoting revenue growth and increasing investment returns. The firm is led by Chairman Brian Montgomery, former Assistant Secretary for Housing and Federal Housing Commissioner, and Vice Chairman Joe Murin, former President and CEO of Ginnie Mae. Both played major roles in the federal governments efforts to address the nations financial crisis and restore stability and liquidity to financial markets. The firms expertise spans all aspects of Agency, non-Agency and FHA/VA housing financing programs; Ginnie Mae securitization activities; domestic and international secondary market activities and issues; primary and special servicing; full asset lifecycle vendor and talent management; and all elements of portfolio due diligence, acquisition, property management and asset disposition.

Visit http://www.directeventreg.com/registration/event/99845500 to register for the call.







Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld

Posted on by


Los Angeles, CA (PRWEB) May 25, 2013

IBISWorld estimates that revenue for the Cell Therapy industry will grow at an average annual rate of 28.7% to $ 1.0 billion in the five years to 2013, including growth of 17.9% in 2013. From 2002 and 2008, no new cell therapy products were introduced, according to IBISWorld industry analyst Kevin Culbert, causing relatively modest growth during that period. In the years since, however, the Food and Drug Administration (FDA) has approved six new products. This factor contributed to the industry’s fast growth during the five years to 2013.

In 2011, the release of Dendreon’s Provenge contributed to revenue growth of 59.5% during the year. The product got a significant boost when Medicare announced that it would cover the cost of reimbursement. In spite of this, the treatment’s reception was expected to be considerably greater. Slow adoption was partially caused by the treatment’s high sticker price (due to its high cost of development), a factor that has led many doctors to use alternative treatments, Culbert says. Industry operators have spent billions of dollars trying to develop a blockbuster treatment that will yield billions of dollars in return. Wage costs contribute significantly to the Cell Therapy industry s high operational costs. In 2013, for example, wages alone are expected to represent 118.5% of industry revenue, causing the industry to operate at a loss throughout its existence.

During that time, industry operators will benefit from the research and development (R&D) that has taken place over the past five years and the clinical trials that are currently in place. The industry will also benefit from the FDA’s Safety and Innovation Act, which was signed into law in July 2012. The act will accelerate the approval process for drug manufacturers, including regenerative medicine products. In spite of this factor, industry firms are expected to continue operating at a loss over the next five years as vast sums of money are poured into R&D. In addition to Dendreon, current major players include Shire Pharmaceuticals, Organogenesis Inc. and NuVasive Inc.

The Cell Therapy industry has a high level of market share concentration. Given that the industry is in the growth stage of its life cycle and it typically takes a number of years to bring a product to market, there is a large number of smaller companies in the industry that are still in the product development stage and awaiting FDA approval. There are currently only about 40 cell therapy products available on the commercial market, according to the Alliance for Regenerative Medicine’s annual report. Consequently, market share concentration is expected to decrease over the next five years as new products are introduced to the commercial market. For more information, visit IBISWorlds Cell Therapy in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry engineers human tissue, also known as cell therapy or regenerative medicine. Tissue engineering is the use of a combination of cells, engineering and materials methods, and suitable biochemical and chemical factors to improve or replace biological functions. Key functions include repairing or replacing tissues (e.g. bone, cartilage, blood vessels and skin).

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nations most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Find More Administrator Press Releases